Close Menu

NEW YORK – Cardea Bio and Nanosens Innovations said today that they are launching an early-access program for the Genome Sensor, a biosensor device based on their CRISPR-Chip graphene transistor technology.

The companies are starting the early-access program ahead of schedule in conjunction with their planned merger, which they also announced today, and will sell CRISPR-Chip technology-based products under the Nanosens brand.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Biohub is working with California's health department to sequence viral samples from COVID-19 patients to trace viral introductions, according to the San Francisco Chronicle.

Despite differences in their migration habits, eastern and western monarch butterflies are genetically similar, according to a study in Molecular Ecology.

The UK is implementing COVID-19 testing with a 90-minute turnaround time.

In PLOS this week: identification of fungal species in subcutaneous infections, sequencing of Campylobacter found in raw meat from retail stores, and more.